Loading
A 22-gene test on the biopsy or surgical specimen that predicts spread and death, used to decide on surveillance or adding hormone therapy.
Decipher Prostate is a genomic classifier run on a whole-transcriptome array of biopsy or surgical tissue; a 22-gene random-forest model gives a score from 0 to 1 that predicts metastasis and prostate cancer death. It is used to choose between surveillance and treatment in localised disease and whether to add hormone therapy to radiation. It was validated on the NRG/RTOG 9601, 0126 and 9902 cohorts, carries NCCN level-1 evidence, and predicts benefit from ADT with radiation in some analyses. It is the basis of the Decipher-stratified trials NRG GU009 and GU010, which test whether intensifying or de-escalating treatment by score improves outcomes. It is complemented and challenged by ArteraAI Prostate, a digital pathology model that works from slide images alone. A newcomer can think of it as a gene test that estimates how aggressive a prostate tumour really is.
Whole-transcriptome array; 22-gene random-forest genomic classifier score 0-1.
1.Decipher Prostate slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Decipher Prostate" OR ABSTRACT:"Decipher Prostate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Decipher Prostate, not a curated reading list.
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Active surveillance, Localised prostate cancer, high and very high risk.
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Active surveillance, Prostate cancer.
Shares Prolaris, RNA sequencing & expression profiling, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Biochemical recurrence of prostate cancer, Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Localised prostate cancer, high and very high risk.